City File: Wellcome gains from sector review
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.IF THERE is a re-rating of the drugs sector, which optimists expect once Bill Clinton elaborates on his healthcare reforms, Wellcome is bound to be a big beneficiary.
Wellcome is not suffering, like some of its rivals, from the general mood to cut healthcare costs, thanks to its specialisation in anti-viral drugs, such as the Aids treatment, Retrovir, and the herpes drug, Zovirax.
Its half-year results, due on Thursday, will show profits rising by a third to about pounds 320m and, while most of its rivals are suffering from a slack first quarter, Wellcome is expected to show that it is powering on.
At 886p, the company's shares trade on 18.5 times this year's expected earnings. This is cheap on a year's view.
(Graph omitted)
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments